Compare Abbott Laboratories (ABT) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Virgin Galactic Holdings, Inc. — how do they compare? Abbott Laboratories trades at $95.93 (market cap $166.94B), while Virgin Galactic Holdings, Inc. trades at $2.54 (market cap $330.34M). The key difference: Abbott Laboratories is far larger — about 505.4× Virgin Galactic Holdings, Inc.'s market cap, and Abbott Laboratories pays a 2.63% dividend while Virgin Galactic Holdings, Inc. pays none. Which is the better fit depends on your goals.
| ABT | SPCE | |
|---|---|---|
Market Cap | $166.94B | $330.34M |
Sector | Health | Industrials |
52-Week High | $136.62 | $7.52 |
52-Week Low | $82.57 | $2.17 |
Enterprise Value | $193.69B | $430.19M |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Virgin Galactic (SPCE) trades at $2.57, down 4.81% today, reflecting persistent bearish technical signals and weak fundamentals. The company continues to report significant losses, with a net income margin of -19,781.3% in 2025 and negative cash flow from operations. Recent news highlights volatility tied to SpaceX IPO developments, with SPCE shares experiencing sharp swings. Analyst consensus is mixed, with 29% buy, 41% hold, and 29% sell ratings, indicating cautious sentiment amid ongoing financial challenges.
The outlook remains highly speculative, with investment opportunity hinging on future commercial spaceflight success, but risks are substantial. High cash burn, lack of profitability, and intense competition threaten shareholder value. Without near-term revenue growth or path to profitability, the stock faces significant downside risk despite trading near historical lows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
